Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL301835 | 0.88 | POLB (0.47) | KDM4ECNR1MEN1KMT2APOLB | |
| SCHEMBL301836 | 0.87 | KDM4E (0.45) | KDM4ECNR1MEN1KMT2APOLB | |
| SCHEMBL3556286 | 0.87 | KDM4E (0.45) | KDM4ECNR1MEN1KMT2APOLB | |
| SCHEMBL3559283 | 0.86 | RAB9A (0.44) | KDM4ECNR1MEN1KMT2APOLB | |
| SCHEMBL3554952 | 0.85 | KDM4E (0.43) | KDM4ECNR1MEN1KMT2APOLB | |
| SCHEMBL3557010 | 0.83 | CARM1 (0.52) | KDM4EMEN1KMT2APOLBMAPT | |
| SCHEMBL3557299 | 0.81 | CCR3 (0.67) | MEN1KMT2APOLBRAB9A | |
| SCHEMBL3563441 | 0.80 | RAB9A (0.42) | KDM4ECNR1MEN1KMT2APOLB | |
| SCHEMBL4857066 | 0.80 | UTS2R (0.68) | KDM4EMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL27661919 | 0.79 | CARM1 (0.56) | MEN1KMT2APOLBMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | KDM4E 1861/4885CNR1 16/4885MEN1 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.